Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis

Tue Jan 29, 2013 8:26pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130130:nGNXUXBFTa

Key Points:

* Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin
Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in
patients with active Rheumatoid Arthritis (RA)
* Trial will be randomized, double-blind placebo-controlled dose escalation study to evaluate the
safety, tolerability and effectiveness of a single intravenous infusion of two MPC dose levels
over an initial period of 3 months in patients who have had poor or incomplete responses to
biologic inhibitors of the TNF-alpha pathway
* Mesoblast's MPCs have been shown in preclinical studies to have a broad immunomodulatory
mechanism of action (MOA), simultaneously inhibiting T cells and monocytes involved in
inflammation and autoimmunity
* In an animal model of RA, MPC treatment significantly decreased the T cell and monocyte derived
inflammatory cytokines TNF-alpha, IL-6 and IL-17 in the diseased joint and reduced tissue
pathology
* MOA provides the rationale for strategic development of MPCs in RA both in patients with
incomplete responses to biologic inhibitors of the TNF-alpha pathway alone and as a first-line
biologic treatment in those not responding to conventional anti-rheumatic agents
* In addition, a second Phase 2 trial of MPCs as a first-line biologic treatment for active RA is
planned to commence in Europe in 1H 2013.

MELBOURNE, Australia, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast
Limited (ASX:MSB) (USOTC:MBLTY), today announced that it has received clearance from the United
States Food and Drug Administration (FDA) to commence a Phase 2 clinical trial evaluating a single
intravenous infusion of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) for the
treatment of active rheumatoid arthritis.

The randomized, double-blind placebo-controlled trial is expected to commence during the second
quarter 2013, and will recruit across multiple sites in the United States and Australia. The trial
will compare the effects of a single intravenous infusion of allogeneic MPCs dosed at 1 or 2
million cells/kg compared with placebo in 48 patients who have had an incomplete or inadequate
response to a biologic inhibitor of the TNF-alpha pathway for active rheumatoid arthritis. Safety
and effectiveness of the MPC therapy will be assessed at multiple time points with the primary
endpoints defined as 3 months.

RA is an autoimmune disease caused by aberrant activation of multiple immune pathways involving
both monocytes and T cells, ultimately resulting in joint destruction. Existing biologic
treatments target only single immune pathways, resulting in incomplete responses, need for chronic
administration, and potentially unacceptable infectious adverse events.

In contrast, Mesoblast's MPCs have been shown in preclinical studies to have a broad
immunomodulatory mechanism of action (MOA), simultaneously inhibiting T cells and monocytes
involved in inflammation and autoimmunity. The broader effects of Mesoblast's MPCs on multiple
immune pathways suggest that they may be particularly useful agents for reducing the inflammation
and permanent joint damage associated with progression of RA.

In a randomized, placebo-controlled study in 30 sheep with collagen-induced arthritis, a model
that manifests joint damage characteristic of human RA, treatment with Mesoblast's MPCs resulted
in reduced TNF-alpha, IL-6, and IL-17 in the diseased joint. In comparison with saline treated
controls, synovial tissue from arthritic sheep 30 days after receiving a single intravenous
injection of 2 million MPCs/kg showed 88% reduction in IL-6 levels (p=0.029), 83% reduction in
TNF-alpha levels (p=0.049), 53% reduction in IL-17 levels (p=0.005), and 43% reduction in
infiltrating monocytes/macrophages (p=0.018). MPC-treated animals had a 31% reduction in
histopathology severity scores compared with controls (p less than 0.025).

These findings show that MPCs can concomitantly inhibit both Th17 T cells and pro-inflammatory
monocytes, and improve synovial tissue pathology. This provides a rationale for their potential
use as both a first-line biologic treatment in those not responding to conventional anti-rheumatic
agents and in patients with incomplete responses to biologic inhibitors of the TNF-alpha pathway
alone.

Mesoblast Chief Executive Professor Silviu Itescu said: "We believe that the broad
immunomodulatory effects of our MPCs could provide a tangible benefit to patients with
debilitating autoimmune diseases, including rheumatoid arthritis. This is the first in a series of
programs designed to establish the credentials of our intravenous product formulation for a
broad-based spectrum of inflammatory and immunologic conditions."

About Rheumatoid Arthritis

RA is a chronic systemic disease characterized by progressive joint deformity and joint
destruction driven by synovial inflammation and hyperplasia in which cytokines play central
pathogenic roles. The prevalence of RA is estimated to be 0.8% worldwide, with women twice as
likely to develop the disease as men. In the United States, RA afflicts 1.3 million people. It is
responsible for 250,000 hospitalizations and 9 million physician visits each year. According to
Global Data, the RA therapeutics market was valued at $10.3 billion globally in 2010, and has
doubled over a four-year period after growing at a Compound Annual Growth Rate (CAGR) of 12.3%.

Mesoblast Limited

Mesoblast Limited is a world leader in the development of biologic products for the broad field of
regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell technology is being
developed for a broad range of major clinical diseases, including inflammatory and immunologic
conditions, diabetes and its complications, orthopedic spine conditions, and cardiovascular
disorders. www.mesoblast.com
http://www.globenewswire.com/newsroom/ctr?d=10019848&l=4&a=www.mesoblast.com&u=http%3A%2F%2Fwww.mesoblast.com

CONTACT: Julie Meldrum
         Global Head of Corporate Communications
         Mesoblast Limited
         T: + 61  3 9639 6036 E: julie.meldrum@mesoblast.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.